Envista (NVST) Competitors $18.02 +0.45 (+2.58%) Closing price 03/27/2025 03:59 PM EasternExtended Trading$18.04 +0.01 (+0.06%) As of 03/27/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NVST vs. PEN, STVN, GKOS, BLCO, INSP, NARI, IRTC, PRCT, TMDX, and SLNOShould you be buying Envista stock or one of its competitors? The main competitors of Envista include Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Inari Medical (NARI), iRhythm Technologies (IRTC), PROCEPT BioRobotics (PRCT), TransMedics Group (TMDX), and Soleno Therapeutics (SLNO). These companies are all part of the "medical equipment" industry. Envista vs. Penumbra Stevanato Group Glaukos Bausch + Lomb Inspire Medical Systems Inari Medical iRhythm Technologies PROCEPT BioRobotics TransMedics Group Soleno Therapeutics Envista (NYSE:NVST) and Penumbra (NYSE:PEN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations, community ranking and risk. Does the media refer more to NVST or PEN? In the previous week, Penumbra had 9 more articles in the media than Envista. MarketBeat recorded 12 mentions for Penumbra and 3 mentions for Envista. Envista's average media sentiment score of 1.20 beat Penumbra's score of 0.97 indicating that Envista is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Envista 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Penumbra 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of NVST or PEN? 88.9% of Penumbra shares are owned by institutional investors. 1.3% of Envista shares are owned by insiders. Comparatively, 5.0% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is NVST or PEN more profitable? Penumbra has a net margin of 1.17% compared to Envista's net margin of -44.56%. Penumbra's return on equity of 9.74% beat Envista's return on equity.Company Net Margins Return on Equity Return on Assets Envista-44.56% 3.86% 2.21% Penumbra 1.17%9.74%7.35% Does the MarketBeat Community prefer NVST or PEN? Penumbra received 796 more outperform votes than Envista when rated by MarketBeat users. Likewise, 80.27% of users gave Penumbra an outperform vote while only 33.33% of users gave Envista an outperform vote. CompanyUnderperformOutperformEnvistaOutperform Votes3433.33% Underperform Votes6866.67% PenumbraOutperform Votes83080.27% Underperform Votes20419.73% Which has higher earnings and valuation, NVST or PEN? Penumbra has lower revenue, but higher earnings than Envista. Envista is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnvista$2.51B1.24-$1.12B-$6.49-2.78Penumbra$1.19B8.67$90.95M$0.34790.84 Do analysts recommend NVST or PEN? Envista presently has a consensus price target of $20.18, indicating a potential upside of 11.95%. Penumbra has a consensus price target of $294.47, indicating a potential upside of 9.51%. Given Envista's higher probable upside, analysts clearly believe Envista is more favorable than Penumbra.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Envista 2 Sell rating(s) 10 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.07Penumbra 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.88 Which has more risk and volatility, NVST or PEN? Envista has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. SummaryPenumbra beats Envista on 15 of the 19 factors compared between the two stocks. Remove Ads Get Envista News Delivered to You Automatically Sign up to receive the latest news and ratings for NVST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVST vs. The Competition Export to ExcelMetricEnvistaDental equipment & supplies IndustryMedical SectorNYSE ExchangeMarket Cap$3.10B$3.64B$5.64B$19.62BDividend YieldN/A2.17%4.57%3.75%P/E Ratio-2.7836.2123.1433.60Price / Sales1.241.39384.1127.47Price / Cash12.916.5738.1617.54Price / Book1.060.716.954.60Net Income-$1.12B-$146.24M$3.20B$1.02B7 Day Performance8.42%0.85%-2.28%0.37%1 Month Performance-9.54%-8.15%2.88%-2.45%1 Year Performance-15.74%224.50%10.87%5.03% Envista Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVSTEnvista4.1731 of 5 stars$18.02+2.6%$20.18+12.0%-16.3%$3.10B$2.51B-2.7812,700PENPenumbra4.4304 of 5 stars$276.24+1.3%$294.47+6.6%+18.9%$10.64B$1.19B812.464,200Insider TradeSTVNStevanato Group1.7052 of 5 stars€20.71+3.4%N/A-36.4%$6.27B$1.10B44.065,635Positive NewsGKOSGlaukos4.4276 of 5 stars$103.12+0.9%$163.25+58.3%+11.8%$5.83B$383.48M-35.93780Insider TradePositive NewsBLCOBausch + Lomb3.9743 of 5 stars$15.39+0.3%$20.00+29.9%-12.9%$5.43B$4.79B-16.9212,500News CoverageGap DownINSPInspire Medical Systems4.8898 of 5 stars$166.59+2.7%$228.82+37.4%-24.6%$4.94B$802.80M96.291,246Positive NewsNARIInari Medical1.0521 of 5 stars$79.97flat$68.00-15.0%N/A$4.68B$493.63M-59.24800IRTCiRhythm Technologies2.0958 of 5 stars$103.70+3.0%$119.73+15.5%-8.3%$3.26B$591.84M-28.491,790News CoveragePositive NewsPRCTPROCEPT BioRobotics2.7097 of 5 stars$59.03+2.4%$94.29+59.7%+26.5%$3.24B$224.50M-30.27430Positive NewsTMDXTransMedics Group2.6238 of 5 stars$67.69-1.2%$122.70+81.3%-5.0%$2.28B$441.54M72.01210Analyst ForecastSLNOSoleno Therapeutics4.6682 of 5 stars$49.63+0.6%$71.20+43.5%+57.3%$2.28BN/A-14.9530Analyst ForecastNews CoverageGap Up Remove Ads Related Companies and Tools Related Companies Penumbra Alternatives Stevanato Group Alternatives Glaukos Alternatives Bausch + Lomb Alternatives Inspire Medical Systems Alternatives Inari Medical Alternatives iRhythm Technologies Alternatives PROCEPT BioRobotics Alternatives TransMedics Group Alternatives Soleno Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NVST) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Envista Holdings Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Envista With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.